The All Wales Therapeutics and Toxicology Centre (AWTTC) produce the National Prescribing Indicators (NPIs). The NPIs show how the different health boards in Wales prescribe certain medicines and highlight any differences in prescribing patterns. They are developed to promote rational prescribing of medicines in Wales and are reviewed every three years. The choice of indicators is evidence-based, and the indicators are designed to be clear and easily understood by prescribers and healthcare professionals.
The indicators allow comparison of current prescribing practice against an agreed standard of quality.
NHS Wales network users can access the majority of the data used in this report via the interactive Server for Prescribing Information and Reporting (SPIRA) dashboards.
In Focus report: Gabapentin and pregabalin. This In Focus report includes supplementary information to that contained within the National Prescribing Indicators 2023-2024. Analysis of prescribing data to March 2024 report, to provide a more detailed picture of gabapentin and pregabalin prescribing across Wales. Analgesics, including gabapentin and pregabalin, are one of the NPI priority areas. The data in this report show prescribing trends for the last two years at a health board, primary care cluster and GP practice level. The percentage of practices meeting the threshold and target achievements are presented. Additionally, it separates out gabapentin and pregabalin prescribing by health board.
⇩ In Focus report - Gabapentin and pregabalin 1.0MB (PDF) |
(Published: April 2026)